Cutting the standard dose of medication for acute mountain sickness in half does not reduce its effectiveness

A new study demonstrated that trekkers and climbers taking a lower dose of acetazolamide (62.5 mg twice daily) were no more likely to develop acute mountain sickness (AMS) symptoms than those who took twice that amount, which is the standard prophylactic dose.